Dimensional Fund Advisors LP Acquires 2,969,856 Shares of Merck & Co., Inc. $MRK

Dimensional Fund Advisors LP lifted its holdings in shares of Merck & Co., Inc. (NYSE:MRK) by 23.8% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 15,456,039 shares of the company’s stock after acquiring an additional 2,969,856 shares during the quarter. Merck & Co., Inc. accounts for about 0.4% of Dimensional Fund Advisors LP’s holdings, making the stock its 23rd largest position. Dimensional Fund Advisors LP owned about 0.63% of Merck & Co., Inc. worth $1,858,938,000 at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of MRK. Kingdom Financial Group LLC. purchased a new stake in shares of Merck & Co., Inc. during the 4th quarter valued at $25,000. Abound Financial LLC bought a new stake in shares of Merck & Co., Inc. during the 4th quarter worth $26,000. Prosperity Bancshares Inc bought a new stake in shares of Merck & Co., Inc. during the 4th quarter worth $26,000. High Note Wealth LLC boosted its holdings in shares of Merck & Co., Inc. by 58.9% in the 4th quarter. High Note Wealth LLC now owns 294 shares of the company’s stock worth $31,000 after buying an additional 109 shares during the last quarter. Finally, IFC & Insurance Marketing Inc. purchased a new position in shares of Merck & Co., Inc. in the 4th quarter worth about $31,000. 76.07% of the stock is currently owned by institutional investors.

Key Headlines Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: The FDA approval of LIPFENDRA gives Merck its first oral PCSK9 inhibitor, opening a new revenue stream in cardiovascular care and strengthening its non-oncology portfolio. Reuters article on FDA approval
• Positive Sentiment: Analysts highlighted continued oncology pipeline progress, including FDA acceptance of multiple regulatory filings and Merck’s broader effort to offset the eventual 2028 Keytruda patent cliff. Seeking Alpha article on pipeline expansion
• Neutral Sentiment: Coverage also noted that Lipfendra’s launch is expected soon and that the drug could become a major product over time, though sales will depend on uptake, pricing, and competition from existing cholesterol therapies. Zacks article on Lipfendra launch
• Neutral Sentiment: There was also a rumor that Merck may be in a takeover battle for genomics company Personalis, but this appears speculative and is not confirmed. Yahoo Finance article on Personalis rumor

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on MRK shares. Royal Bank Of Canada restated an “outperform” rating and set a $142.00 price objective on shares of Merck & Co., Inc. in a report on Wednesday, July 8th. Morgan Stanley boosted their target price on shares of Merck & Co., Inc. from $112.00 to $113.00 and gave the company an “equal weight” rating in a research note on Thursday, July 9th. CICC Research started coverage on shares of Merck & Co., Inc. in a research note on Wednesday, June 24th. They set an “outperform” rating and a $138.00 price target for the company. Weiss Ratings lowered shares of Merck & Co., Inc. from a “hold (c+)” rating to a “hold (c)” rating in a research note on Friday, May 15th. Finally, Guggenheim lifted their price target on shares of Merck & Co., Inc. from $140.00 to $145.00 and gave the stock a “buy” rating in a report on Monday, July 13th. One research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and seven have given a Hold rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $133.94.

Merck & Co., Inc. Trading Down 0.0%

Shares of MRK opened at $127.47 on Monday. The business has a 50-day moving average of $120.11 and a 200 day moving average of $117.01. Merck & Co., Inc. has a fifty-two week low of $76.66 and a fifty-two week high of $131.74. The firm has a market cap of $314.83 billion, a P/E ratio of 35.91, a price-to-earnings-growth ratio of 5.04 and a beta of 0.19. The company has a debt-to-equity ratio of 1.02, a quick ratio of 1.06 and a current ratio of 1.30.

Merck & Co., Inc. (NYSE:MRK) last announced its quarterly earnings data on Thursday, April 30th. The company reported ($1.28) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.47) by $0.19. The business had revenue of $16.29 billion for the quarter, compared to analysts’ expectations of $15.85 billion. Merck & Co., Inc. had a return on equity of 27.55% and a net margin of 13.59%.The firm’s quarterly revenue was up 4.9% compared to the same quarter last year. During the same period in the previous year, the business posted $2.22 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. As a group, research analysts forecast that Merck & Co., Inc. will post 2.76 EPS for the current year.

Merck & Co., Inc. Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Wednesday, July 8th. Stockholders of record on Monday, June 15th were given a $0.85 dividend. The ex-dividend date of this dividend was Monday, June 15th. This represents a $3.40 annualized dividend and a dividend yield of 2.7%. Merck & Co., Inc.’s payout ratio is 95.77%.

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.